Bio-Rad Laboratories (NYSE:BIO) Announces Quarterly Earnings Results

Bio-Rad Laboratories (NYSE:BIO) issued its quarterly earnings results on Thursday. The medical research company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.86 by $0.04, Zacks reports. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. Bio-Rad Laboratories updated its FY 2025 guidance to EPS.

Bio-Rad Laboratories Trading Down 7.2 %

NYSE BIO traded down $22.18 during trading hours on Friday, hitting $284.18. 307,190 shares of the company’s stock were exchanged, compared to its average volume of 172,294. The stock has a 50-day simple moving average of $339.70 and a 200 day simple moving average of $336.52. Bio-Rad Laboratories has a 1-year low of $262.12 and a 1-year high of $387.99. The firm has a market cap of $7.96 billion, a price-to-earnings ratio of -10.40 and a beta of 0.90. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16.

Analyst Ratings Changes

BIO has been the subject of several recent research reports. StockNews.com raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. Royal Bank of Canada reissued an “outperform” rating and issued a $481.00 price target on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Citigroup increased their price target on Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, Wells Fargo & Company decreased their price target on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a research note on Wednesday. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $395.20.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.